Regulatory Strategy is the documented plan that defines how a medical device will achieve and maintain market authorization across target regions. It maps the device classification, applicable regulations (such as FDA 21 CFR Part 820 and EU MDR 2017/745), submission pathway, and evidence requirements from early development through post-market surveillance.
What is Regulatory Strategy?
A regulatory strategy is the plan a manufacturer uses to bring a medical device to market and keep it there. It sits at the front of the device lifecycle, usually drafted during concept and feasibility, then refined at each phase gate. Quality Assurance and Regulatory Affairs (QARA) teams typically own it, working alongside engineering and clinical.
At its core, the strategy answers three questions. What is the device, in regulatory terms? Where will it be sold? And how will the manufacturer prove it is safe and performs as intended? The answers connect intended use, device classification, target jurisdictions, submission route, and evidence requirements into one coherent plan.
Why Regulatory Strategy matters in medical device development
Classification drives almost everything downstream. Get it wrong and the submission pathway, testing burden, and clinical evidence all shift, often after significant work is already done. A device wrongly scoped as low risk can face rejection, a hold, or a forced reclassification that resets the timeline and the budget.
The consequences are not only commercial. Regulators tie market authorization to demonstrated safety and performance, so a weak strategy can leave patient-facing risks unaddressed until an audit or a field issue surfaces them. Under the FDA Quality Management System Regulation (QMSR), effective February 2, 2026, 21 CFR Part 820 now incorporates ISO 13485:2016 by reference, and inspectors can review design and risk records directly. In the EU, EU MDR 2017/745 applies in full, with the first EUDAMED modules mandatory from May 28, 2026. A strategy set early keeps these obligations visible before they become expensive.
Key components of a regulatory strategy
A working regulatory strategy usually covers the following elements:
- Intended use and indications for use. The precise clinical claim frames everything else, including classification and evidence.
- Device classification. Class I, II, or III under FDA rules; Class I, IIa, IIb, or III under EU MDR 2017/745. IVDs follow their own class A to D scheme under the IVDR.
- Target markets and sequencing. Which jurisdictions come first, and in what order, based on commercial priority and approval difficulty?
- Submission pathway. For the U.S., a 510(k), De Novo request, or premarket approval (PMA). For the EU, the applicable conformity assessment route and notified body involvement.
- Applicable standards. ISO 13485 for quality systems, ISO 14971 for risk management, plus product standards such as IEC 60601-1 for electrical safety or IEC 62304 for device software.
- Clinical and performance evidence. What data proves safety and performance: bench testing, biocompatibility, clinical investigation, or literature and equivalence?
- Post-market plan. Post-market surveillance, vigilance reporting, and periodic updates are required once the device is on the market.
Each element feeds the next. Classification sets the pathway, the pathway sets the evidence bar, and the evidence bar shapes the design and test plan. Building these links early and recording the rationale gives the team a defensible position when a regulator or auditor asks why a given route was chosen.
Common challenges and best practices
The most common failure is treating regulatory work as a final gate rather than a design input. When RA joins late, teams discover that the chosen predicate does not fit, the clinical data is thin, or the classification was optimistic. Reworking a submission at that stage is slow and costly.
Misjudging classification is a close second. Borderline products, software functions, and devices with new intended uses often sit between classes, and an aggressive read can trigger a refusal to accept or a request for a full clinical dataset.
A few practices separate smooth programs from stalled ones:
- Fix intended use and classification early, and revisit them whenever the design changes.
- Use regulator dialogue before you submit. FDA pre-submission (Q-Sub) meetings and EU structured processes surface problems while they are still cheap to fix.
- Tie the strategy to design controls and the risk file so evidence is generated as a byproduct of development, not scrambled together at the end.
- Do not assume one market’s clearance transfers. FDA clearance does not grant a CE mark, and the reverse is equally true.
How SJML helps with Regulatory Strategy
SJML runs regulatory strategy as part of its Compliance-as-a-Service offering. Its QARA team supports device classification and pathway planning across major frameworks, including FDA 510(k) and premarket approval, CE marking, and EU MDR and IVDR registration, along with country-specific routes and technical file preparation. That work is backed by quality systems aligned to ISO 13485 and MDSAP, and risk management files built to ISO 14971. With design, engineering, manufacturing, and compliance under one roof, strategy decisions stay connected to the teams that execute them.
Frequently asked questions
As early as the concept or feasibility phase, before major design decisions are locked. Classification and intended use shape the submission pathway and evidence requirements, so setting them early prevents costly rework. The strategy is a living document, revisited at each phase gate and whenever the design, intended use, or target markets change during development.
A regulatory pathway is the specific submission route for a device, such as a 510(k), De Novo, or PMA in the U.S. A regulatory strategy is the broader plan that selects that pathway and ties it to classification, target markets, applicable standards, and the evidence needed. The pathway is one output of the strategy, not the whole thing.
No. FDA clearance or approval applies only to the U.S. market. Selling in the European Union requires a CE mark under EU MDR 2017/745, with its own classification rules, conformity assessment, and notified body review for higher-risk devices. A regulatory strategy sequences these markets and plans the separate evidence and documentation each one demands.
Quality Assurance and Regulatory Affairs (QARA) usually leads the regulatory strategy, but it is a cross-functional effort. Engineering, clinical, and product teams all contribute, since classification and evidence decisions affect design, testing, and timelines. In smaller companies, this responsibility is often outsourced to a regulatory partner or a fractional RA lead who coordinates across the program.
Related terms
- Device Classification
- 510(k) Submission
- Conformity Assessment
- Design Controls
- Post-Market Surveillance
